The clinic panel, part 1:
the ten chronic conditions

1. Hypertension. The panel’s most common diagnosis and the one most often mismanaged by measurement error: accurate technique, confirmation outside the office where possible, and treatment intensified rather than observed indefinitely. The value question is cheap accuracy and generic drugs: home or ambulatory confirmation prevents both overtreatment of white-coat elevation and undertreatment of masked hypertension, and first-line agents are inexpensive generics whose combinations are usually better tolerated than maximum doses of one. The intern owns: the technique actually performed correctly in clinic, therapeutic inertia recognized as a real error, and the follow-up interval short enough to make titration possible — the classic intern pattern is a perfect assessment followed by “recheck in six months.”

2. Type 2 diabetes. Among the fastest-moving evidence bases in primary care: glycemic targets individualized rather than universal,³ and agent selection now driven as much by cardiac and kidney benefit as by glucose lowering. The Standards of Care are revised annually and are the reference of record. The value question is cost as a clinical variable: the agents with the strongest outcome evidence are frequently the most expensive, and a prescription the patient cannot afford does not work — asking about cost is part of prescribing, not a courtesy. The intern owns: the complication screening that runs on a schedule (eyes, feet, kidneys), the glycemic target agreed rather than assumed, hypoglycemia asked about at every visit, and the self-management education referral whose glycemic effect rivals a medication adjustment.

3. Lipids and cardiovascular risk. Managed as risk, not as a number: current practice estimates risk with a validated calculator, uses the estimate to frame a shared decision, and treats with statins first because that is where the outcome evidence overwhelmingly sits. The value question is the risk-based conversation: the calculator is free and the statins are generic; the low-value patterns are treating a lipid value without a risk estimate, reflexive advanced lipid panels, and non-statin add-ons chosen before adherence has been asked about. The intern owns: a documented risk estimate, the shared decision that lets the patient participate, and the statin-intolerance conversation done properly — rechallenge and alternatives — rather than closed with “patient refuses.”

4. Obesity and weight management. Treated as a chronic disease and no longer an advice-only field: current care combines behavioral and dietary support with pharmacotherapy of substantial efficacy and metabolic surgery for appropriate candidates, in a landscape moving fast enough that any specific drug statement dates quickly. The value question is access and honesty: the effective agents are costly and coverage is inconsistent, so the plan must be built around what this patient can actually obtain and sustain; and the cheapest, most durable interventions remain the behavioral supports and the referrals that go unmade. The intern owns: raising the subject respectfully and with permission, treating weight as a modifiable clinical factor rather than a moral one, the comorbidity screening that changes management, and knowing what your system and its payers actually cover.

5. Chronic kidney disease. Now defined by cause, filtration, and albuminuria together — and albuminuria is the piece most often left unmeasured, which is why the current KDIGO framework insists on it.⁴ The therapeutic story has changed substantially: agents once thought of as diabetes drugs now carry kidney and cardiovascular outcome evidence in defined populations. The value question is the cheap test that changes everything: a urine albumin-to-creatinine ratio is inexpensive and reclassifies risk, while the reflex renal ultrasound in every patient with a mildly reduced filtration rate is a classic low-value order. The intern owns: the albuminuria actually ordered, nephrotoxins reviewed at every visit, drug doses adjusted to real function, blood pressure and glucose managed as kidney therapy, and the nephrology referral made at the point the guideline defines rather than when the numbers frighten someone.

6. Asthma and COPD in the clinic. Two diseases with distinct guidance — GINA and GOLD respectively, both revised frequently — sharing one clinic failure: nobody watches the patient use the inhaler. The approach: confirm the diagnosis with spirometry rather than presumption, treat by current severity or exacerbation-risk framework, and reassess control at defined intervals. The value question costs nothing: observed inhaler technique and adherence review outperform escalation, and stepping up therapy for uncontrolled symptoms without checking either is the classic error in both diseases — common, expensive, and named in both guidelines. The reliever strategy itself has changed fundamentally in recent years: teach it from the current GINA, not from memory. The intern owns: spirometry before a lifelong label, the technique watched and corrected at the visit, vaccinations and smoking cessation as disease-modifying therapy, and the written action plan the patient can actually follow.

7. Heart failure in the clinic. The outpatient half of the ward’s most frequent readmission: the evidence now supports early, layered, guideline-directed therapy titrated over months rather than the slow sequential approach many were taught, with the ejection fraction defining which pathway applies. The value question is titration versus surveillance: the value is created by the visits that adjust therapy — brief, frequent, focused — while repeat echocardiography in a stable patient without a management question adds cost and no benefit. The intern owns: a titration plan with dates, the electrolytes and renal function that titration moves (the fluids-and-electrolytes hour), the weight-and-symptom self-monitoring taught with teach-back, and the post-discharge visit that actually happens.

8. Thyroid disease. High-volume, mostly straightforward, and a reliable generator of low-value testing: the approach is a sensible testing strategy, treatment of overt disease, and honest uncertainty in subclinical disease — where treatment benefit is genuinely debated and age and antibody status matter. The value question is testing discipline: thyroid function rechecked more often than the physiology can change, the panel ordered when one test would do, ultrasound for a normal gland, and treatment titrated by symptoms alone are all common and all wasteful. The intern owns: the appropriate testing interval after any change, the timing and absorption counseling that fixes many “refractory” cases, and resisting treatment of a number in a patient who feels well — while taking seriously the patient who does not.

9. Osteoarthritis and chronic musculoskeletal pain. Among the most common reasons patients come, and where the evidence favors what is hardest to deliver: exercise and physical therapy, weight management, and topical or non-opioid systemic agents, with imaging reserved for cases where it will change management and opioids playing a narrow, cautious role. The value question is the imaging cascade: early imaging for uncomplicated low back pain is among medicine’s most-cited low-value practices² — it finds age-appropriate changes, worsens patients’ beliefs about their backs, and generates procedures without improving outcomes. The intern owns: the red-flag assessment that justifies not imaging, the function-focused conversation (“what can’t you do that you want to do?”), the referral to therapy actually made, and honest expectation-setting about what medication can and cannot deliver.

10. Prevention and cancer screening. The most distinctly outpatient work on the list and the reason continuity exists: immunizations, cancer screening by current recommendation, and cardiovascular and metabolic risk reduction — all delivered on schedules, over years, to people who feel well. Recommendations differ between bodies and change; the current USPSTF statements and your system’s own protocols are the reference. The value question is the shared decision at the margins: the population benefit of screening is real and so are its harms, which is why several recommendations sit in the shared-decision zone rather than the automatic one, and why screening people who will not benefit — because of age or limited life expectancy — is both a value failure and a clinical harm. The intern owns: the gaps identified during pre-charting rather than discovered at the door, the offer made even when the visit is about something else, the shared decision documented, and the follow-up on abnormal results, which fails far more often than the screening itself.